These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28414846)

  • 1. Clinical trials in Latin America: implications for the sustainability and safety of pharmaceutical markets and the wellbeing of research subjects.
    Homedes N; Ugalde A
    Salud Colect; 2016; 12(3):317-345. PubMed ID: 28414846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted.
    Homedes N; Ugalde A
    Bull World Health Organ; 2015 Oct; 93(10):674-683. PubMed ID: 26600609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study.
    Homedes N; Ugalde A
    PLoS One; 2016; 11(6):e0157756. PubMed ID: 27336585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Brazil: agricultural modernisation and food production restructuring in the international crisis].
    Bertrand JP
    Tiers Monde (1960); 1985; 26(104):879-98. PubMed ID: 12267623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confidentiality agreements: a challenge in market regulation.
    Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
    Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pharmaceutical industry and the sustainability of healthcare systems in developed countries and in Latin America].
    Iñesta A; Oteo LA
    Cien Saude Colet; 2011 Jun; 16(6):2713-24. PubMed ID: 21709969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of researchers loyal to Big Pharma on the ethics and quality of clinical trials in Latin America].
    Ugalde A; Homedes N
    Salud Colect; 2015 Mar; 11(1):67-86. PubMed ID: 25853831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
    Pichon-Riviere A; Garay OU; Augustovski F; Vallejos C; Huayanay L; Bueno Mdel P; Rodriguez A; de Andrade CJ; Buendía JA; Drummond M
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):2-11. PubMed ID: 25989703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical research and drug development in Latin America: weighing the pros and cons, talking about the future.
    Rodrigues DG
    J Investig Med; 2007 Jul; 55(5):223-9. PubMed ID: 17850733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of comparative efficacy data at the time of drug approval in the United States.
    Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
    JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affordably priced new drugs for poor populations: Approaches for a global solution.
    Mossialos E; Dukes G
    Int J Risk Saf Med; 2001; 14(1):1-29. PubMed ID: 22388482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.